Cassava Sciences simufilam reduces seizures 60% in TSC mouse model; H1 2026 clinical trials planned

FILANA THERAPEUTICS, INC.

Preclinical data: simufilam reduced seizure frequency by 60% vs. vehicle in focal onset seizure mouse model (p<0.0001).
More mice achieved seizure freedom: 11/32 simufilam vs. 3/29 vehicle (p=0.0343).
Human safety data from 1,929-patient Phase 3 Alzheimer's studies show favorable safety profile with no serious SAEs attributed to drug.
Company plans to initiate first clinical study in TSC-related epilepsy in H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.